Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for the Treatment of Metastatic Melanoma Patients

Trial Profile

Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for the Treatment of Metastatic Melanoma Patients

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Ipilimumab (Primary) ; T cell replacement therapy (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
    • 21 May 2017 Status changed from recruiting to discontinued due to toxicity of cyclophosphamide.
    • 27 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top